Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

Overview

The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient cured with nephrectomy and multiple metastasectomies followed by Cabozantinib, while he was judged to be on palliative care, three years ago.

Summary

The importance of this case is that the patient was judged to be on palliative care, three years ago, and now he is having a normal life. The use of cabozantinib after Sunitinib failure was successful, but we think that it is the metastasectomy who had a benefic effect on disease free survival of our patient without any recurrence under cabozantinib. No data exists on the effect of metastasectomy before cabozantinib, this is why we think that this case allows us to discuss one more time, the indication of metastasectomy in the management of metastatic RCC.

Author Comments

Dr Johnny Boustany, MD
Dr Johnny Boustany, MD
Notre Dame Des Secours University Medical Center
Dr
Urology
Byblos | Lebanon
It's a pleasure to share this case that highlights the important role of surgery in the treatment of renal cancer, despite the imperative role of medical treatment.Dr Johnny Boustany, MD

Resources

https://www.oncotarget.com/article/27543/text/
https://www.oncotarget.com/article/27543/text/

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

Oncotarget

Boustany J., Abdessater M., Hachem C. El, Khoury Z. El, Khoury W. El, Khoury R. El Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib. Oncotarget. 2020; 11: 1922-1928. Retrieved from https://www.oncotarget.com/article/27543/

https://doi.org/10.18632/oncotarget.27543  Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy.  The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib.  Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life.  Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach. 
May 2020
100 Reads

Similar Publications